{"nctId":"NCT00789737","briefTitle":"Welchol as Monotherapy for Type 2 Diabetes Mellitus","startDateStruct":{"date":"2009-01"},"conditions":["Type 2 Diabetes Mellitus"],"count":357,"armGroups":[{"label":"Welchol","type":"EXPERIMENTAL","interventionNames":["Drug: Welchol"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Welchol","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects \\>= 18 years of age;\n* Women of childbearing potential (WOCBP) must be using an adequate method of contraception as detailed in the protocol.\n* Diagnosis of Type 2 Diabetes Mellitus;\n* HbA1C \\>= 7.5% and =\\< 9.5 % at screening;\n* Fasting C-peptide \\>0.5 ng/mL at screening;\n* Drug na√Øve (no prior treatment with OAD) or having received no pharmacologic therapy for diabetes for the 3 month period prior to screening;\n* Clinically stable in regards to medical conditions other than type 2 diabetes;\n* Concomitant medications must be at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period; and\n* Fasting glucose =\\< 240 mg/dL at randomization\n\nExclusion Criteria:\n\n* A history of type 1 diabetes and/or a history of ketoacidosis;\n* History of bowel obstruction;\n* History of hypertriglyceridemia-induced pancreatitis;\n* Fasting serum triglyceride concentrations \\>500 mg/dL;\n* History of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal (GI) motility disorders, or major GI surgery;\n* History of insulin use of \\>= 2 weeks duration in the previous 3 months or a total of \\> 2 months of insulin therapy at any time prior to screening;\n* Two or more fasting self-monitored blood glucose (SMBG) levels \\>240 mg/dL during the placebo lead-in period.\n* Previous treatment with a bile acid sequestrant, including Welchol within the 3 months prior to screening;\n* Body mass index (BMI) \\>40 kg/m2;\n* Weight loss \\> 3% in prior 3 months; and\n* LDL \\<60 mg/dL.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Hemoglobin A1c","description":"change in HbA1c from baseline to Week 24","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":".091"},{"groupId":"OG001","value":"-0.14","spread":"0.091"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose","description":"to determine changes in Glycemic control after 24 weeks on therapy","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"3.45"},{"groupId":"OG001","value":"5.7","spread":"3.51"}]}]}]},{"type":"SECONDARY","title":"% Subjects With a Decrease in HbA1c of >= 0.7 Percentage Units","description":"to determine the percentage of participants who experience a reduction in HbA1c of at least 0.7 percentage units at 24 weeks from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.1","spread":null},{"groupId":"OG001","value":"19.5","spread":null}]}]}]},{"type":"SECONDARY","title":"% Subjects Achieving an HbA1C Goal of <7.0","description":"% Subjects achieving an HbA1C goal of \\<7.0 at 24 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"13.6","spread":null}]}]}]},{"type":"SECONDARY","title":"% Subjects With a Decrease in FPG >=30 mg/dL","description":"% Subjects with a decrease in Fasting Plasma Glucose \\>=30 mg/dL from baseline to 24 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.9","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Total Cholesterol [TC]","description":"To assess the effects of Welchol on changes in total cholesterol \\[TC\\]","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"1.02"},{"groupId":"OG001","value":"1.8","spread":"1.03"}]}]}]},{"type":"SECONDARY","title":"Changes in Low Density Lipoprotein Cholesterol [LDL-C]","description":"To assess the effects of Welchol on changes in low density lipoprotein cholesterol \\[LDL-C\\]","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":"1.62"},{"groupId":"OG001","value":"1.2","spread":"1.63"}]}]}]},{"type":"SECONDARY","title":"Changes in High Density Lipoprotein Cholesterol [HDL-C]","description":"To assess the effects of Welchol on changes in high density lipoprotein cholesterol \\[HDL-C\\]","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.19"},{"groupId":"OG001","value":"-0.1","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Changes in Non-HDL-C","description":"To assess the effects of Welchol on changes in non-HDL-C","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"1.34"},{"groupId":"OG001","value":"3.0","spread":"1.36"}]}]}]},{"type":"SECONDARY","title":"Changes in Triglycerides [TG]","description":"To assess the effects of Welchol on changes in triglycerides \\[TG\\]","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":"39.82"},{"groupId":"OG001","value":"5.8","spread":"38.39"}]}]}]},{"type":"SECONDARY","title":"Changes in Apolipoprotein A-I (apoA-I)","description":"To assess the effects of Welchol on changes in apolipoprotein A-I (apoA-I)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"0.80"},{"groupId":"OG001","value":"0.9","spread":"0.81"}]}]}]},{"type":"SECONDARY","title":"Changes in Apolipoprotein B (apoB)","description":"To assess the effects of Welchol on changes in apolipoprotein B (apoB)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"1.18"},{"groupId":"OG001","value":"0.9","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Change in Postprandial Plasma Glucose, 2 Hours After a Meal Tolerance Test","description":"To assess the change from baseline on postprandial plasma glucose, 2 hours after a meal tolerance test","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.3","spread":"5.72"},{"groupId":"OG001","value":"-1.5","spread":"5.86"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":175},"commonTop":["urinary tract infection","headache","nasopharyngitis","diabetes mellitus","diarrhoea"]}}}